EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) to a strong-buy rating in a report released on Monday, Zacks.com reports.
A number of other brokerages have also recently commented on NRXP. HC Wainwright lifted their price objective on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Ascendiant Capital Markets boosted their target price on NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 12th.
Get Our Latest Report on NRx Pharmaceuticals
NRx Pharmaceuticals Stock Up 0.8 %
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.06. Analysts expect that NRx Pharmaceuticals will post -3.25 EPS for the current fiscal year.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- How to Invest in the FAANG Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Are the FAANG Stocks and Are They Good Investments?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Most active stocks: Dollar volume vs share volume
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.